Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123


Safety and immunogenicity of neonatal pneumococcal conjugate vaccination in Papua New Guinean children: a randomised controlled trial.

Pomat WS, van den Biggelaar AH, Phuanukoonnon S, Francis J, Jacoby P, Siba PM, Alpers MP, Reeder JC, Holt PG, Richmond PC, Lehmann D; Neonatal Pneumococcal Conjugate Vaccine Trial Study Team.

PLoS One. 2013;8(2):e56698. doi: 10.1371/journal.pone.0056698. Epub 2013 Feb 22.


Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.

Esposito S, Tansey S, Thompson A, Razmpour A, Liang J, Jones TR, Ferrera G, Maida A, Bona G, Sabatini C, Pugni L, Emini EA, Gruber WC, Scott DA, Principi N.

Clin Vaccine Immunol. 2010 Jun;17(6):1017-26. doi: 10.1128/CVI.00062-10. Epub 2010 Apr 28.


13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trial.

Silfverdal SA, Flodmark CE, Rombo L, Tansey SP, Sidhu M, Trammel J, Emini EA, Gruber WC, Scott DA, Gurtman A; 3012 study group.

Vaccine. 2013 Feb 18;31(9):1284-92. doi: 10.1016/j.vaccine.2012.12.066. Epub 2013 Jan 7.


Immunogenicity of a 7-valent pneumococcal conjugate vaccine (PCV7) and impact on carriage in Venezuelan children at risk of invasive pneumococcal diseases.

Rivera-Olivero IA, Del Nogal B, Fuentes M, Cortez R, Bogaert D, Hermans PW, Waard JH.

Vaccine. 2014 Jun 30;32(31):4006-11. doi: 10.1016/j.vaccine.2014.04.027. Epub 2014 May 14.


Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.

Bryant KA, Block SL, Baker SA, Gruber WC, Scott DA; PCV13 Infant Study Group.

Pediatrics. 2010 May;125(5):866-75. doi: 10.1542/peds.2009-1405.


Immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine as a booster dose in 12- to 18-month-old children primed with 3 doses of 7-valent pneumococcal conjugate vaccine.

Thisyakorn U, Chokephaibulkit K, Kosalaraksa P, Benjaponpitak S, Pancharoen C, Chuenkitmongkol S.

Hum Vaccin Immunother. 2014;10(7):1859-65. doi: 10.4161/hv.28642.


Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants.

Zangwill KM, Greenberg DP, Chiu CY, Mendelman P, Wong VK, Chang SJ, Partridge S, Ward JI.

Vaccine. 2003 May 16;21(17-18):1894-900.


Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants.

Wijmenga-Monsuur AJ, van Westen E, Knol MJ, Jongerius RM, Zancolli M, Goldblatt D, van Gageldonk PG, Tcherniaeva I, Berbers GA, Rots NY.

PLoS One. 2015 Dec 10;10(12):e0144739. doi: 10.1371/journal.pone.0144739. eCollection 2015. Erratum in: PLoS One. 2016;11(5):e0155088.


Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.

Vanderkooi OG, Scheifele DW, Girgenti D, Halperin SA, Patterson SD, Gruber WC, Emini EA, Scott DA, Kellner JD; Canadian PCV13 Study Group.

Pediatr Infect Dis J. 2012 Jan;31(1):72-7. doi: 10.1097/INF.0b013e318233049d.


Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy.

Abzug MJ, Song LY, Levin MJ, Nachman SA, Borkowsky W, Pelton SI; International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1024 and P1061s Protocol Teams.

Vaccine. 2013 Oct 1;31(42):4782-90. doi: 10.1016/j.vaccine.2013.08.002. Epub 2013 Aug 14.


Randomised, controlled trial of concomitant pneumococcal and meningococcal conjugate vaccines.

Wysocki J, Tansey S, Brachet E, Baker S, Gruber W, Giardina P, Arora A.

Vaccine. 2010 Nov 16;28(49):7779-86. doi: 10.1016/j.vaccine.2010.09.047. Epub 2010 Sep 28.


Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants: a randomized clinical trial.

Spijkerman J, Veenhoven RH, Wijmenga-Monsuur AJ, Elberse KE, van Gageldonk PG, Knol MJ, de Melker HE, Sanders EA, Schouls LM, Berbers GA.

JAMA. 2013 Sep 4;310(9):930-7. doi: 10.1001/jama.2013.228052.


The Antibody Response Following a Booster With Either a 10- or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy.

Trück J, Jawad S, Goldblatt D, Roalfe L, Snape MD, Voysey M, Pollard AJ.

Pediatr Infect Dis J. 2016 Jul;35(7):787-93. doi: 10.1097/INF.0000000000001180.


Comparison of two-dose priming plus 9-month booster with a standard three-dose priming schedule for a ten-valent pneumococcal conjugate vaccine in Nepalese infants: a randomised, controlled, open-label, non-inferiority trial.

Hamaluba M, Kandasamy R, Upreti SR, Subedi GR, Shrestha S, Bhattarai S, Gurung M, Pradhan R, Voysey M, Gurung S, Pradhan S, Thapa AK, Maharjan R, Kiran U, Kerridge SA, Hinds J, van der Klis F, Snape MD, Murdoch DR, Kelly S, Kelly DF, Adhikari N, Thorson S, Pollard AJ.

Lancet Infect Dis. 2015 Apr;15(4):405-14. doi: 10.1016/S1473-3099(15)70007-1. Epub 2015 Feb 18.


Immunogenicity of seven-valent pneumococcal conjugate vaccine administered at 6, 14 and 40 weeks of age in South African infants.

Jones SA, Groome M, Koen A, Van Niekerk N, Sewraj P, Kuwanda L, Izu A, Adrian PV, Madhi SA.

PLoS One. 2013 Aug 28;8(8):e72794. doi: 10.1371/journal.pone.0072794. eCollection 2013.


Immunogenicity, safety and tolerability of 3 lots of 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in the United States.

Payton T, Girgenti D, Frenck RW, Patterson S, Love J, Razmpour A, Sidhu MS, Emini EA, Gruber WC, Scott DA.

Pediatr Infect Dis J. 2013 Aug;32(8):871-80. doi: 10.1097/INF.0b013e3182906499.


Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to korean children receiving routine pediatric vaccines.

Kim DS, Shin SH, Lee HJ, Hong YJ, Lee SY, Choi KM, Oh CE, Kim KH, Juergens C, Patterson S, Giardina PC, Gruber WC, Emini EA, Scott DA.

Pediatr Infect Dis J. 2013 Mar;32(3):266-73. doi: 10.1097/INF.0b013e3182748bb6.


The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial.

Dagan R, Givon-Lavi N, Porat N, Greenberg D.

Vaccine. 2012 Jul 20;30(34):5132-40. doi: 10.1016/j.vaccine.2012.05.059. Epub 2012 Jun 6.


The future of pneumococcal disease prevention.

Rodgers GL, Klugman KP.

Vaccine. 2011 Sep 14;29 Suppl 3:C43-8. doi: 10.1016/j.vaccine.2011.07.047.


Supplemental Content

Support Center